Two studies were undertaken to investigate the effects of acute (Study 1) or repeated (Study 2) administration of the angiotensin converting enzyme (ACE) inhibitor enalapril on the cognitive deficits produced by scopolamine administration in volunteers. Enalapril at doses between 2.5 and 10.0 mg p.o. produced virtually complete blockade of plasma ACE activity. However, it did not influence the effects of scopolamine on a variety of cognitive tasks, including tests of memory, attention and sedation.
Get full access to this article
View all access options for this article.
References
1.
Barnes J.M., Barnes N.M., Costall B., Coughlan J., Horovitz Z.P., Kelly M.E., Naylor R.J., Tomkins D.M. (1989) ACE inhibitors and cognition In MacGregor, G A, Sever, P S (eds), Current advances in ACE inhibition.Churchill Livingstone, Edinburgh, pp. 159-171
2.
Bond A.J., Lader M.H. (1974) The use of analogue scales in rating subjective feelings, Br J Med Psychol47: 211-218
3.
Broks P., Preston G.C., Traub M., Poppleton P., Ward C., Stahl S.M. (1988) Modelling dementia: effects of scopolamine on memory and attentionNeuropsychologia26: 685-700
4.
Cohen M.L., Kurz K. ( 1983) Captopril and MK-421: stability on storage, distribution to the central nervous system, and onset of activityFed Proc42: 171-175
5.
Costall B., Horowitz Z.P., Kelly M.E., Naylor R.J., Tomkins D.M. (1988) Captopril improves basic performance and antagonises scopolamine impairment in a mouse habituation testBr J Pharmacol95: 882P
6.
Costall B., Coughlan J., Horowitz Z.P., Kelly M.E., Naylor R.J., Tomkins D.M. (1989) The effects of ACE inhibitors captopril and SQ29,852 in rodent tests of cognitionPharmacol Biochem Behav33: 573-579
7.
Currie D., Lewis R., McDevitt D.G., Nicholson A.N., Wright A.N. (1989) Central effects of the angiotensin-converting enzyme inhibitor, captopril, in healthy volunteersBr J Clin Pharmacol28: 228P
8.
Gerhards H.J., Hock F.J., Leven U., Stechl J., Wiember G. (1988) Central nervous system effects of lipophilic ACE-inhibitors in rodents: behavioral and biochemical evidenceSoc Neurosci Abstr14 (Part 1): 149
9.
Hock F.J., Stechl J., Rieger W. (1989) Enhancing effects of Hoe 065 on different learning tasks in mice and ratsNaunyn-Schmiedeberg's Arch Pharmacol339 (Suppl.): R105
10.
Jarden J.O., Barry D.I., Juhler M., Graham D.I., Standgaard S., Paulson OB (1984) Cerebrovascular aspects of converting-enzyme inhibition II: Blood-brain barrier permeability and effect of intracerebroventricular administration of captoprilJ Hypertension2: 599-604
11.
Kopelman M.D. (1986) The cholinergic neurotransmitter system in human memory and dementia: a reviewQ J Exp Psychol38A: 535-573
12.
Mondadori C., Etienne P. (1990) Nootropic effects of ACE inhibitors in micePsychopharmacology100: 301-307
13.
Olajide D., Lader M. (1985) Psychotropic effects of enalapril maleate in normal volunteersPsychopharmacology86: 374-376
14.
Preston G.C., Brazell C., Ward C., Broks P., Traub M., Stahl S.M. (1988) The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in manJ Psychopharmacol2: 67-79
15.
Preston G.C., Ward C., Lines C.R., Poppleton P., Haigh J R M, Traub M. (1989) Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigminePsychopharmacology98: 487-494
16.
Wiemer G., Becker R., Gerhards H., Hock F., Stechl J., Ruger W. (1989) Effects of Hoe 065, a compound structurally related to inhibitors of angiotensin converting enzyme, on acetylcholine metabolism in rat brainEur J Pharmacol166: 31-39
